PubHawk
Front Cell Dev Biol July 2020 PMID 32793604

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.

Qingyang Lei, Dan Wang, Kai Sun, Liping Wang, Yi Zhang

Download social card

Mentions

4
Peak: 2 in Jul 2020
across 2 sources since Jul 2020

Extended reach

11,356
potential audience

Total likes

113

Video views

3,836

Mentions per month

Jul 2020 – Jun 2022

Where it's discussed

  • X / Twitter3 posts
  • YouTube1 videos

AI synopsis

What people are saying

Discussion leaders show high interest by emphasizing how tumors evolve to avoid immune attacks and the significance of blocking signaling pathways, with phrases like 'resistance mechanisms' and 'strategies to overcome resistance,' reflecting their focus on advancing immunotherapy. Their tone conveys enthusiasm for the potential to improve treatments, highlighting the importance of the research's implications.

AgreementModerate agreement

Most discussions acknowledge the importance of understanding tumor resistance mechanisms, supporting the publication's focus.

InterestHigh interest

There is high curiosity about how tumors evade immune detection and the potential for new therapies.

EngagementModerate engagement

Participants reference complex concepts like immune signaling and resistance strategies, indicating active engagement.

ImpactModerate impact

The discussion suggests recognition that this research could influence future cancer treatment approaches, but does not assume immediate change.

Abstract in brief

  • The text explains how the PD1 and PDL1 proteins work together to help tumors avoid immune attacks, and how blocking these proteins has been effective in treating some cancers, but many patients do not respond or develop resistance over time.
  • It highlights various resistance mechanisms, such as tumors being less recognizable by the immune system, T cell exhaustion, problems with immune signaling, and immunosuppressive environments, which make therapy less effective.
  • The review also discusses potential biomarkers for predicting responses and strategies to overcome resistance, aiming to improve the success of antiPD1/PDL1 cancer immunotherapies.
Read the full abstract

Top posts

Most liked on X and Bluesky
Mark Paris
@geneman10 · X

@RadarContact13 @NPR This isn't a matter of immune fitness. Some tumors evolve to express a signal that prevents recognition and detruction by T-cells. The drug used in this trial blocks that signaling. https://t.co/2os6DYN7Os https://t.co/lKMbiQSV7b

Jun 12, 2022 · 4 likes · 565 followers View post →
Frontiers - Cell Biology
@FrontCellDevBio · X

New Research: Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors: In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as accomplices to help tumors resist to immunity-induced apoptosis and promote tumor… https://t.co/N0tzNcnw9J #celldevbio

Jul 21, 2020 · 3 likes · 1 share · 3,802 followers View post →

All mentions

Mark Paris
@geneman10 · X

@RadarContact13 @NPR This isn't a matter of immune fitness. Some tumors evolve to express a signal that prevents recognition and detruction by T-cells. The drug used in this trial blocks that signaling. https://t.co/2os6DYN7Os https://t.co/lKMbiQSV7b

Jun 12, 2022 · 4 likes · 565 followers View post →
lisaporter2
@LisaPorter2 · X

RT @FrontCellDevBio: New Research: Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors: In cancer-immunity cycle, the immune che…

Jul 21, 2020 · 1 share · 3,150 followers View post →
Frontiers - Cell Biology
@FrontCellDevBio · X

New Research: Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors: In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as accomplices to help tumors resist to immunity-induced apoptosis and promote tumor… https://t.co/N0tzNcnw9J #celldevbio

Jul 21, 2020 · 3 likes · 1 share · 3,802 followers View post →